Comprehensive Optimization of Rules! The 11th Batch of National Procurement Opens Bidding Today, Involving 55 Varieties and Over 400 Companies Competing

    The 11th National Centralized Drug Procurement officially commenced accepting submissions from companies at 7:30 AM today in Qingpu District, Shanghai, with public disclosure of application information scheduled to begin at 10:30 AM. This round covers 55 drug varieties involving over 400 companies, averaging 14 companies per variety. Products like cefazolin injection and dapagliflozin oral immediate-release formulations generated billions in sales in 2024. Major participants include Hengrui Medicine, Qilu Pharmaceutical, Zhengda Tianqing, Shijiazhuang Pharmaceutical Group, and AstraZeneca, each submitting multiple varieties.

    Note: According to previously released documents for the 11th National Procurement, this round features comprehensively optimized rules. Adhering to the principles of “stabilizing clinical use, ensuring quality, preventing internal competition, and guarding against bid rigging,” it introduces several innovations: Each company must commit to bidding at or above cost. Companies submitting lower bids must also declare the reasonableness of their pricing, thereby guiding the market toward healthy competition.